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Introduction.  In Tanzania, palliative care is relatively new, and faces the 
common challenges of access to services, crucial medications, and 
education.  Since 2004, an initiative within the health system of the 
Evangelical Lutheran Church in Tanzania (ELCT) began to promote and 
develop palliative care, using as a model the Selian Hospice and Palliative 
Care Programme.  The hospitals which are the sites for team development 
and service delivery are widely scattered throughout rural Tanzania.  Access 
to oral morphine was only a dream, as it is for much of the rural population 
of the world.  In 2007, a program called CHAT (Continuum of care for 
people living with HIV/AIDS in Tanzania), funded by the U.S. government, 
allowed the up-scaling of these palliative care programs, resulting in 13 
strong and mature teams by 2011, though still lacking oral morphine.  Part of 
the monitoring and quality assurance of the program has been use of a tool 
developed by APCA:  the APCA African Palliative Outcome Scale (POS).  
Hundreds of people living with cancer and HIV were subjected to the 
questions of the tool, which was always sent on to the core supervising team 
for assessment and feedback.  Tramadol was the strongest analgesic 
available to the teams throughout the study time. 
Methodology:  145 APCA African POS results on cancer patients were 
assessed, looking at differences in pain scores (0 to 5 scale) over time as 
well as assessing the other domains of care (psychological, spiritual, social, 
and family).  11 Palliative care nurses were also interviewed, asked to reflect 
on specific cases from their experience with both good and bad pain control.  
5 of the nurses came from Selian, with access to oral morphine, while 6 of 
them came from the CHAT hospitals. 
Results:  Significa t improvement in pain scores over 4 weeks was noted 
(3.83 to 2.31, p < 0.0001).  All other domains assessed in the POS also 
improved significantly.  Nurse interviews revealed an emphasis on the 
holistic approach and a strong preference for having access to oral morphine. 
Conclusion:  In this rural Tanzanian environment, effective palliative care 
services – including pain control - were delivered even in the absence of oral 
morphine.  Such services can become a strong advocacy at the government 
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1.1  Palliative Care 
Palliative care is a critical component of the medical approach to life-
threatening diseases, particularly with incurable conditions such as terminal 
cancer.  In rural Tanzania, as in much of the world, diagnosis of cancer 
occurs late in the clinical course of disease, with the result that palliative 




The World Health 
Organization (WHO) defines palliative care as a holistic approach for 
patients and their families who are living with life-threatening diseases.  One 
emphasis is on the ability to treat pain holistically, including the provision of 
medication to alleviate that pain
3
.  Yet few palliative care services are 
available, most particularly in rural parts of the world, due to a lack of 
trained professionals, a lack of medication (opioids especially), and a lack of 
integration into standard medical care
4
.  A recent analysis out of the 
International Observatory on End of Life Care shows that just over 50% of 
the world’s countries have any form of palliative care, and of those a further 




1.2  Relief from Pain 





But while ongoing adv cacy is working towards recognition of 
pain relief as a basic human right
4,7
, it is of limited availability in much of 
the world.  The result being that people living with cancer are often left to 
die at home, or in the hospital, with no effective way to relieve their physical 
suffering.  Most of the world’s population has access to little or no opioid 




1.3  Study Setting/Tanzania 
Tanzania is a country of over 40 million people, and it is estimated that over 
50,000 people per year will die of cancer
9
. Due primarily to vast distances to 
travel and the immobility of the very sick, less than 10% of this population 
might access a palliative care service.  Even when such a service is 
available, oral morphine may be in limited supply, and follow-up 
(reassessments, refills) is usually very challenging. 
 
Palliative care is relatively new to Tanzania.  Initial efforts came from the 
Ocean Road Cancer Institute (ORCI) in Dar es Salaam, headed by Dr. 
Twalib Ngoma, and this institution continues to provide leadership in this 











However it was not until the turn of the century that other sites began 
concerted efforts at palliative care provision.  By 2002 there were three 





Consumption of morphine remains low in Tanzania.  Per capita consumption 
of morphine in 2005 is listed at 0.51 mg per capita
8
.This compares to 6 mg 
per capita for South Africa and 565 mg per capita in the United States.  In 
the case of Tanzania, if only a quarter of the people estimated to have cancer 
in 2010 would need oral morphine continuously for moderate to severe pain 
(50,000/4 = 12,500), and only 20 mg daily were required for pain control, it 
would take 2.28 mg per capita consumption to meet that need (based on a 
current population of roughly 40 million).  Considering that Kenya, with 
more widely available oral morphine than Tanzania, used a per capita 
consumption of about 1 mg per capita, it is unlikely that Tanzania is 
approaching anything near the necessary consumption to achieve pain 
control for a significant portion of their population living with cancer. 
 
1.4  Selian and ELCT 
In 2004, the Evangelical Lutheran Church in Tanzania (ELCT) began a 
program in palliative care, emulating the growth of Selian's service.    Using 
a hospital-based approach, trained palliative care teams were developed 
through 18 rural ELCT hospitals, widely scattered throughout the country 
(see Map in Appendix I).  In 2007 the ELCT program, in collaboration with 
the Foundation for Hospices in Sub-Saharan Africa (FHSSA) and the 
African Palliative Care Association (APCA), received funding from the 
President’s Emergency Program for AIDS Relief (PEPFAR, out of the 
United States) to initiate the program now known as CHAT (Continuum of 
Care for people living with HIV/AIDS in Tanzania)
11-14
. Tanzania is one of 
the target countries for PEPFAR.  Its approach, as organized by the National 
AIDS Control Program (NACP), is to provide home-based care (HBC) to all 
people living with HIV, with the spectrum of HIV services available either 
at the nearby health facility or the home.  Trained community volunteers (a 
21 day curriculum organized by the NACP), health professional supervisors, 
counselling and testing, anti-retroviral drug access, and palliative care are all 
part of this spectrum.  The CHAT program is unique in several aspects:  
starting with pre-existing palliative care services; having a supervising 
multi-disciplinary team; having a mobile team with vehicle transport; being 
inclusive of non-HIV cases, cancer in particular; and monitoring quality of 











HBC service based at the hospital, a multi-disciplinary team of professionals 
providing oversight and backup care to a larger team of lay volunteers from 
the community.  Care is provided in homes, on hospital wards, at hospital-
based outpatient clinics, and through mobile clinics. 
 
1.5  Rural areas and access to oral morphine 
As mentioned above, oral morphine is not accessible in most of rural 
Tanzania, including these 13 sites (13 of the 18 ELCT hospitals are part of 
CHAT).  Thus the practice of pain management has been in the context of 
significant limitations.  As a result each team of health professionals has 
become proficient in the systematic use of other analgesics, namely, 
tramadol, ibuprofen, and paracetamol as analgesics for somatic pain, and 
amitriptyline and carbamazapine for treatment of neuropathic pain.  These 
medications are provided free of charge to their clients by the respective 
palliative care teams. 
 
This experience of provision of palliative care raises questions.  Whereas 
studies have shown the benefit for people living with HIV to be linked to 
HBC programs
15
, there is little information about such care for cancer 
patients where oral morphine is lacking.  While it might be intuitive that 
global well-being for any patient would be enhanced by attention from a 
multidisciplinary team – in the ELCT hospitals a Nurse, Nurse Assistant, 
Clinician, Social Worker, and Chaplain – there is still the issue of physical 
pain.  What is the perceived efficacy of such care when morphine is not 
available?  Is this experience able to be generalized to other settings? 
 
Traditional palliative care development has focused on three key issues as 
outlined by the WHO:  inclusion in national health policy, education, and 
availability of oral morphine
16
.With the advent of wide-spread home care 
and anti-retroviral therapy for people living with HIV, however, the 
landscape of palliative care in Tanzania has changed.  Fewer people with 
HIV are dying, with palliative care efforts in areas of high HIV prevalence 
now finding their biggest challenges in psychosocial and reproductive 
issues:  stigma, disclosure, and human rights in regards to autonomy in 




Pain management as being 
integral to palliative care remains critical in the HIV context, but it is now in 
a different and perhaps less prominent position as opportunistic infections 
are less common and world-wide clinical experience steers treatment 














Widespread home care programs in Tanzania emphasize care for people 
living with HIV, many of whom also have cancer (Kaposi's Sarcoma, 
cervical cancer, lymphomas), and yet these programs lack any special focus 
on effective treatment of pain.  Indeed, oral morphine is only reliably 
available in 5 sites country-wide:  Ocean Road Cancer Institute, PASADA, 
Muheza, Selian and, since September 2009, Kilimanjaro Christian Medical 
Centre
10
.  Practically, this means that only the Northeast and Coastal parts of 
the country have the possibility of ready access to this drug.  Even where 
oral morphine is available, the combination of a limited number of 
prescribers (only Medical Doctors may prescribe), limited education for 
health professionals, and even limited stocks of the drug means that very few 
people in need are likely to receive it. 
 
1.6  Study Purpose and Research Questions 
The purpose of this study was to assess the quality of palliative care for 
cancer patients in rural Tanzania as provided by palliative care teams, 80% 
of whose clients are living with HIV.  In this context oral morphine is not 
available and it might be some years before it is.  Teams are nonetheless 
trained in the use of the WHO Analgesic Ladder, attempting to treat 
moderate to severe pain for HIV and cancer patients with the drugs which 
they have at their disposal.  These drugs include tramadol, ibuprofen, 
diclofenac, and paracetamol. 
 
What is the effect on palliative care services when the most important tool 
for treating pain – oral morphine - is not available?  What insights have been 
gained by the nursing profession in meeting the challenges of working with 
such limited resources?  What difference would oral morphine make if it 






















2. Literature Review 
 
2.1  Opioid Availability 
The WHO in 2002 included in its definition of palliative care “effective 
assessment and treatment of pain and other problems whether physical, 
psychological, or spiritual”. Oral morphine, or its equivalent, is the gold 
standard for treating moderate to severe cancer pain
19-21
. Step 3 on the WHO 
Analgesic Ladder refers to use of strong opioids i.e. an opioid that does not 




Logie found that most of the world is without access to oral morphine, and 
even where morphine is legally available its use is very low due to fears 
concerning addiction and consequent tight regulations
22
. While world-wide 
advocacy for accessing oral morphine is a main priority in the development 
of palliative care, the current picture is not encouraging
23
.The implication of 
limited to no access to a strong opioid drug is that effective pain 
management is not possible in such environments.  Gwyther et al, and 
Human Rights Watch, emphasize that in advocacy work access to palliative 





The Step 2, or weak opioid class of drugs, are less restricted by the Single 
Convention on Narcotic Drugs
24
 but are also less effective in relieving pain.  
Little is written about the provision of palliative care for cancer patients in 
the absence of Step 3 (strong opioid) drugs.  A literature review failed to 
find any papers addressing such care.  Yet anecdotal communications with 
colleagues in East Africa and India indicate that such situations exist, 
whether because of interrupted supply of oral morphine or because of being 
in an area which has yet to have access to oral morphine. 
 
Widely observed but likewise little published is that the usual doses of 
opioid drugs in East Africa tend to be much lower than those in Europe or 
North America.  Daily dosing of morphine in East Africa is commonly in the 
20 to 30 mg range, with a “big” dose approaching 60 mg/day (personal 
communication with prescribers at Muheza Hospice, ORCI, PASADA, and 
Nairobi Hospice from 2010-2011).  Yet there is little information in the 
literature regarding this phenomenon.  A review of oral morphine use at 
Selian Hospice in northern Tanzania in 2008 revealed an average daily dose 
of oral morphine to be 27 milligrams; in 2009 it was 24 mg/d.  An in-patient 
service in Malawi uses an average daily dose of 30 mg/d
25











paper assessing the Edmonton Staging System for cancer pain lists doses 
less than 60 mg/d of oral morphine as “low” and doses greater than 300 
mg/d as “high”
26
. An assessment of oral morphine in chronic cancer pain 





In Tanzania tramadol is currently the most widely available weak opioid 
drug.  Its pain control properties have been well studied, and it is considered 
a WHO “Step 2” analgesic drug, having a usual dosing ceiling of 400 
mg/day in adults
28
.  Dose equivalency tables vary in ascribing a tramadol to 
morphine potency ratio from 10:1 to 20:1
29,30
.  One study out of Germany 
compared high dose tramadol (average 428 mg/d) with low dose morphine 
(42 mg/d) and found comparable efficacy in terms of pain control and less 
side-effects in the tramadol group
31
. Thus, in theory, tramadol might be 
useful in the treatment of mild to moderate cancer pain in East Africa, 
though unable to match the potency of higher doses of morphine.  Additional 
limitations of tramadol include limited efficacy, if any, in the treatment of 
dyspnoea (no references relating studies of tramadol in dyspnoea treatment).  
Also, being mostly available in capsule form (though intravenous also 
available) makes dosing versatility a problem, for example when much 
lower doses are needed for children, or with obstructing cancers such as that 
of carcinoma of the oesophagus.  Therefore, while a lot of information about 
tramadol exists, there is no existing literature regarding its utility when there 
are not any more potent opioids available. 
 
2.2  Pain Assessment in Africa 
Careful pain assessment is one of the core principles of delivering effective 
palliative care.  This has been true in African palliative care service delivery 




have been used in 
various country settings.  Additionally, there has been the development of a 
broader assessment tool, the APCA African Palliative Care Outcome Scale 
(APCA African POS), which utilizes a 0 to 5 scale and the 5 digits of the 
hand as the visual corollary.  This broader approach to pain – psychological, 
social, spiritual, and family questions also come in - is in keeping with the 
palliative care approach towards holistic assessment.  It is also aligned with 
the concept of “total pain”, whereby as many facets of suffering in a 
person’s life as possible are considered, with the goal of achieving pain 













The advent of the APCA African POS in 2007 provided the continent with a 
validated tool for holistic assessment that had been tested in a variety of 
African contexts
33,34
,  Harding et al point out that it also gives palliative care 
in the African setting a standardized tool with which to measure outcomes, 
including pain
35
.  That pain is very prevalent in cancer patients in Africa – as 
elsewhere – is well known
36,37
.  In a study of cancer patients in Uganda and 
South Africa, Harding et al offer further information, highlighting the 
prevalence of pain and other symptoms.  They found that 87% of such 




Being relatively new, literature is limited on the use of the APCA African 
POS in terms of measured outcomes over a period of time (typically being 4 
visits 1 week apart in the context of ongoing palliative care services).  Loy et 
al used this tool, and show clearly that those outcomes for people living with 
HIV are better if provided in the context of a palliative care team
39
. While 
showing the improvement in quality of life for such patients living with HIV 
and receiving palliative care, there is no information regarding people living 
with cancer. 
 
Another question in the area of intervention for pain relief:  how much pain 
relief is necessary such that a patient finds it meaningful?  Or, in terms of 
using a pain scale such as the 0 to 10 visual analogue, what degree of pain 
reduction is meaningful?  Farrar et al noted that a 20 to 30% improvement in 
chronic pain patients (non-cancer) was needed in order to be associated with 
meaningful changes in other quality of life indicators i.e. sleep, mobility
40,41
. 
Traditionally, palliative care uses a change of 20% to be considered of 
significant impact, although extensive searching could not find an evidence 
base for this standard.  Fainsinger et al suggest a 3/10 pain rating (or less) 




2.3  Rationale for the Study:  Literature is lacking about the efficacy and 
quality of palliative care for cancer patients in environments which lack 
access to potent opioid drugs such as oral morphine.  Yet such patients 
desperately need holistic care, including attention to pain and other 
symptoms, even if the ideal drugs and tools are not yet available.  From 
experience and personal communication, people clearly appreciate holistic 
care, particularly within their home environments, yet the question remains:  
what is the quality of such care when the primary medical tool (oral 
morphine for effective pain control) is lacking?  Are there lessons to be 











Tanzania, where limited or no access to certain drugs is a fact of life, 



















































3.1  Aim:  to assess the effect of limited or no access to oral morphine on the 
delivery of palliative care in rural Tanzania. 
 
3.2  Objectives: 
 To use a retrospective cohort analysis to assess the effectiveness, from 
the patient’s perspective, of weak opioid analgesia in cancer pain 
management in rural Tanzania. 
 To assess patient outcomes in quality of life areas as evaluated by the 
APCA African POS for people living with cancer and receiving 
palliative care in rural Tanzania. 
 To assess the effectiveness of palliative care of cancer patients in both 
morphine-accessible and morphine non-accessible environments in 
Tanzania from the palliative care nursing perspective. 
 To assess the impact on palliative care nursing staff on the provision 
of palliative care to cancer patients in morphine-accessible and 
morphine non-accessible environments in Tanzania. 
 
There are two aspects to the research.  The first aspect is a quantitative study 
involving a retrospective cohort analysis of cancer patients who do not have 
access to oral morphine.  The second aspect is a qualitative analysis of 
interviews with 11 palliative care nurses, 6 from teams not having access to 
oral morphine and 5 from a team having access to oral morphine. 
 
3.3  The Retrospective Cohort Analysis:  As outlined above, as part of the 
CHAT project’s ongoing quality assessment the APCA African POS was 
administered to all new patients having cancer and at one or two new HIV 
clients each month.  CHAT began its formal training, including the APCA 
African POS, with 7 hospital teams in November of 2007 and 6 hospital 
teams in February of 2008.  Subsequent site visits as well as larger all-
hospital meetings emphasized review and observation of how the APCA 
African POS was being administered.  A “learning curve” time was 
definitely present; by January of 2009 all teams had become well-versed in 
administration and reporting of this tool.  Thus results from the APCA 
African POS, for the purposes of this study, are considered valid from 
January 2009 onwards. 
 











Coordinator of the team or the part-time Team Clinician.  Training and 
ongoing follow-up was given to both cadres throughout the project and study 
period. 
 
Pain management was uniformly taught and mentored to all of the teams.  
Tramadol was administered to all patients with severe pain, up to a 
maximum dose of 400 mg/d.  Combining with ibuprofen, paracetamol, 
and/or amitriptyline was done according to patient response and tolerability.  
There were no shortages of any of these drugs throughout the study period. 
 
Reports were submitted to the central ELCT office on a monthly basis.  
Feedback on reports was done electronically (email).  All data was 
transcribed by the researcher from hard copy to the online database used by 
the CHAT project.  Hard copy and online data remain available for review 
and analysis. 
 
The APCA African POS is meant to be administered four times over a 
period of 2 to 4 weeks.  It has been validated for people over the age of 18 
years and with a variety of disease conditions
36
. Swahili was the working 
language in all instances, and the version being used was unchanged 
throughout the study time. 
 
For the purposes of this study, only people living with cancer, being over 18 
years of age, and having been assessed at least 3 times using the APCA 
African POS were included.  
 
3.4  Study Population: 
 
i. Selection criteria: 
1. Inclusion 
a. Over 18 years 
b. Cancer as a diagnosis (including some 
people with HIV) 
c. Assessed at least 3 times out of the possible 
4 for APCA POS 
2. Exclusion 
a. Under 18 years of age 
b. non-cancer diagnosis 
c. Died before completion of APCA POS 











e. Incomplete charting of the APCA POS 
 
ii. Sampling:  all CHAT program cancer patients between 
January 2009 and December 2010.  It is generally 
accepted that a meaningful reduction in pain is at least 
20%. Calculation of sample size is based on that number 
needed to show that a 20% drop in pain is statistically 
significant; if indeed the CHAT interventions result in a 
significant pain reduction.  The minimal number of 
patients to be evaluated was calculated to be 100. 
 
 
Those people who died before the requisite number of visits were 
completed, or who had incomplete charting of the POS, were excluded.  
Although many clients were assessed multiple times with the APCA African 
POS, only the first set of visits is included for purposes of this study. 
 
The period of time included in the analysis is January 2009 up to December 
2010. 
 
3.5  Analysis of the Retrospective Cohort Analysis:  Statistical analysis was 
organized so as to have all of the data compiled in Microsoft Excel format.  
Analysis was done using Excel software (“Analyse it”).  Comparison in pain 
levels (on a 0 to 5 scale) are made between the first and last visit (visit 1 vs. 
visit 4) as ascertained on the APCA African POS Question 1. 
 
The Shapiro-Wilk test was used to investigate whether numerical variables 
were normally distributed.  For bivariate analysis the Wilcoxon Sum Rank 
test was applied to compare groups.  Descriptive analysis was done based on 
sites, age, and gender.  Key outcome variables were pain and overall quality 
of life measures: 
i. Comparison in pain levels (on a 0 to 5 scale) were 
assessed between first and last visit as ascertained on the 
APCA POS Question number one. 
ii. Comparison in quality of life change was assessed by 
calculating a global score (total APCA POS score 
organized so that for each question the “0” represents the 















3.6  The Qualitative Analysis of two groups of Palliative Care Nurses:  Two 
groups of palliative care nurses were subjected to semi-structured interviews 
(Appendix VII).  All nurses have extensive training and experience in the 
field of palliative care.  5 nurses are from the Selian Hospice and Palliative 
Care Programme, which has had access to oral morphine since 2003.  The 
other 6 nurses are from various CHAT hospitals, none of which had access 
to oral morphine during the time of the study.  Each nurse was asked about 
specific cases regarding pain control in patients having cancer:  one case 
where pain control was poor; another case where pain control was very 
good.  Each interview concluded with a question about the value of 
delivering palliative care in the absence of oral morphine, and then an 
invitation to the nurse to make any general closing remarks.  A further 
question evolved as it became clear from the Selian nurses that the only 
cases of poor pain control were not using oral morphine:  “Do you recall any 
cases of patients using oral morphine where the pain was not controlled?” 
 
The CHAT Nurses were chosen as being the most experienced out of the 
group of 13 Nurses.  3 hold Diplomas in Palliative Care; the other 3 have at 
least 7 years of experience in PC.  All of the Selian cadre of Nurses were 
interviewed.  Their experience in PC ranges from 5 to 12 years.  As Pickard 
describes it in her book on research methods this was purposeful sampling in 
two regards
43
. First, the most experienced and knowledgeable of the CHAT 
Nurses were chosen.  Secondly, of the few palliative care nurses in 
Tanzania, those at Selian represent a long-term experience within a system 
comparable to that of the CHAT Nurses.   
 
Interviews were conducted in Swahili (9) or English (2) by the researcher, 
after informed consent was obtained from each of the respective nurses.  
Translation (Swahili to English) and transcription were likewise performed 
by the researcher.  After audio recording of each interview, transcription was 
done for the 2 English interviews, while transcription and translation were 
simultaneous for the 9 Swahili interviews. 
 
3.7  Analysis of the Nurse Interviews:  Thematic analysis was done looking 
for common areas of thought shared by the nurses being interviewed, with 
attention to there being the two different groups, one having access to oral 
morphine and the other not.  As suggested by Aronson,
 
thematic analysis is 













 Patterns of information, or themes, are identified.  Within each 
theme there may also be sub-themes.  The collection of sub-themes and 
themes should inform a comprehensive view of the information collected. 
 
Medical and nursing peer review – within the ELCT health system – of the 
translations and transcripts was done, in order to cross-check for the validity 
of the comments made by nurses who had been interviewed.  As the peers 
involved had personal knowledge of each nurse, this process was helpful in 
affirming the trustworthiness and objectivity of the data. 
 
3.8  Ethical Considerations:  Ethical approval for this study was granted by 
the University of Cape Town and also the National Institute of Medical 
Research of Tanzania (see Appendices). 
 
Approval for use of data was requested from FHSSA, APCA, and each 
hospital site from which data was collected.  Consent for the Nurse 
interviews was requested in each case (see Appendices for letters requesting 
consent). 
 
Confidentiality was maintained with the nurse interviews by keeping 
recordings and transcriptions in a secure, locked place.  The nurses are only 
identified by number, with the key to the particular names kept locked up.  
For the patient data, the researcher’s office only has access to “patient 
numbers”, with the key to the patient names kept at the respective sites.  
Thus names are not known to the researcher. 
 
Data storage were kept in two sites:  hard copies in a locked file and office; 

























4.1  Retrospective Cohort Analysis 
145 APCA African POS administered to cancer patients qualified for 
inclusion in the study in the area of pain control (Question 1).  All 13 sites 
contributed, although the distribution varied widely.  2 sites had only 1 fully 
completed and eligible APCA POS while 3 sites had more than 20.  
Morphine was not available at any of the sites.  There were more female (87) 
than male (58) patients (60% to 40%).  The average age was 57 years.  See 
Table 1 for disaggregation by site and gender, with average first and last 
pain scores also noted for each site. 
 
An Excel spreadsheet captured the data for all 145 patients.  Table 2 shows 
the average APCA POS scores for each visit.  Tables 3 and 4 show the 
averages by gender.  In questions 4 through 9 the numbers are reversed 
(highlighted in blue).  This is in order to align the numbers so that all “high” 






























TABLE 1:  Disaggregation by Site and Gender 
 
HOSPITAL # Avg. 
Age 






Matema 26 54 15 11 4.42 2.46 
Itete 13 58 7 6 3.00 1.92 
Haydom 21 52 6 15 3.10 3.00 
Bunda 8 43 4 4 4.75 3.38 
Marangu 6 59 3 3 4.00 1.67 
Bumbuli 6 58 2 4 3.33 1.67 
Iambi 23 54 7 16 3.52 1.91 
Ndolage 8 69 3 5 5.00 1.00 
Nyakahanga 9 61 2 7 4.11 2.56 
Nkoaranga 7 64 1 6 2.57 2.00 
Ilembula 1 55 0 1 3.00 2.00 
Gonja 1 56 1 0 3.00 3.00 
Machame 16 64 7 9 4.56 2.63 











Table 2:  Average Scores per Visit 
 
Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) during 
the last 3 days 
 
 
0 (no pain) 
- 5 (worst/overwhelming pain) 
Visit 1 Visit 2 Visit 3 Visit 4 
  3.83   3.08   2.72   2.31 
 
Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been affecting 
how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.58 
 
  2.05 
 
  1.68 
 
  1.50 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.39 
 
  2.67 
 
  2.31 
 
  2.10 
 
Q4. Over the past 3 days, have you been able to share how you are feeling with 
your family or friends? 
 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.46/ 
  1.54 
  3.84/ 
  1.16 
  4.06/ 
  0.94 
  4.15/ 
  0.85 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  1.95/ 
  3.05 
  2.52/ 
  2.48 
  2.94/ 
  2.06 
  2.95/ 
  2.05 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.80/ 
  3.20 
  2.39/ 
  2.61 
  2.73/ 
  2.27 
  2.84/ 
  2.16 
 
Q7 Have you had enough help and advice for your family to plan for the future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  2.94/ 
  2.06 
  3.70/ 
  1.30 
  3.99/ 
  1.01 
  4.08/ 
  0.92 
 
Q8. How much information have you and your family been given? 
0 (none) 




  3.30/ 
  1.70 
 
  4.01/ 
  0.99 
 
  4.40/ 
  0.60 
 
  4.63/ 
  0.37 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.09/ 
  0.91 
  4.34/ 
  0.66 
  4.45/ 
  0.55 
  4.46/ 
  0.54 
 
Q10. Has the family been feeling worried about the patient over the last 3 days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  3.08 
 
  2.58 
 
  2.19 
 
  2.10 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 
 
   2.53   1.96   1.63   1.49 
Table 3:  Average Scores  Female 











Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) during 
the last 3 days 
0 (no pain) 
- 5 (worst/overwhelming pain) 
  3.71   2.99   2.67   2.31 
 
Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been affecting 
how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.57 
 
  2.02 
 
  1.55 
 
  1.47 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.44 
 
  2.75 
 
  2.41 
 
  2.27 
 
Q4. Over the past 3 days, have you been able to share how you are feeling with 
your family or friends? 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.41/ 
  1.59 
  3.79/ 
  1.21 
  3.94/ 
  1.06 
  4.03/ 
  0.97 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  2.01/ 
  2.99 
  2.49/ 
  2.51 
  2.93/ 
  2.07 
  2.85/ 
  1.90 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.84/ 
  3.16 
  2.36/ 
  2.64 
  2.70/ 
  2.30 
  2.75/ 
  2.25 
 
Q7 Have you had enough help and advice for your family to plan for the future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  2.81/ 
  2.19 
  3.64/ 
  1.36 
  3.87/ 
  1.13 
  3.99/ 
  1.01 
 
Q8. How much information have you and your family been given? 
0 (none) 
- 5 (as much as wanted) 
N/A 
 
  3.28/ 
  1.72 
  3.95/ 
  1.05 
  4.31/ 
  0.69 
  4.49/ 
  0.51 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.07/ 
  0.93 
  4.32/ 
  0.68 
  4.44/ 
  0.56 
  4.41/ 
  0.59 
 
Q10. Has the family been feeling worried about the patient over the last 3 days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  3.14 
 
  2.58 
 
  2.21 
 
  2.16 
 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 
  
  2.54 
 
  1.98 
 
  1.67 
 
  1.54 
Table 4:  Average Scores Male 
 
Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) during 
the last 3 days 
 
 
0 (no pain) 
- 5 (worst/overwhelming pain) 
Visit 1 Visit 2 Visit 3 Visit 4 












Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been affecting 
how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.59 
 
  2.09 
 
  1.86 
 
  1.55 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.31 
 
  2.54 
 
  2.14 
 
  1.81 
 
Q4. Over the past 3 days, have you been able to share how you are feeling with 
your family or friends? 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.52/ 
  1.48 
  3.91/ 
  1.09 
  4.22/ 
  0.78 
  4.33/ 
  0.67 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  1.86/ 
  3.14 
  2.57/ 
  2.43 
  2.97/ 
  2.03 
  3.10/ 
  1.90 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.74/ 
  3.26 
  2.45/ 
  2.55 
  2.78/ 
  2.22 
  2.98/ 
  2.02 
 
Q7 Have you had enough help and advice for your family to plan for the future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  3.12/ 
  1.88 
  3.79/ 
  1.21 
  4.17/ 
  0.83 
  4.22/ 
  0.78 
 
Q8. How much information have you and your family been given? 
0 (none) 
- 5 (as much as wanted) 
N/A 
 
  3.33/ 
  1.67 
  4.11/ 
  0.89 
  4.54/ 
  0.46 
  4.67/ 
  0.33 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.11/ 
  0.89 
  4.38/ 
  0.62 
  4.48/ 
  0.52 
  4.53/ 
  0.47 
 
Q10. Has the family been feeling worried about the patient over the last 3 days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  2.98 
 
  2.59 
 
  2.16 
 
  2.02 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 












Overall, each and every domain shows improvement over time.  The “worst” 
problem overall is pain for both men and women.  This is true for both the 
first and fourth visits.  For the first visit the average pain score is 3.83, with 
the next worst score being that of anxiety (question 3) at 3.39.  However by 
the fourth visit pain has a very close average score (2.31) to that of several 
other symptoms e.g. question 3 (anxiety, 2.10) and question 6 (sense of 
peace, 2.16). 
 
Statistical analysis was done comparing the average pain level recorded at 
the first visit with that of the fourth visit (highlighted in Table 2).  First the 
Shapiro-Wilk test was administered for checking for normal distribution in 
both first and fourth visits of each of the questions – not only for pain, but 
the other 9 questions as well.  Table 5 (below) shows the results, indicating 
that the distributions are not “normal”.  Thus instead of the t-test, the 
Wilicoxon test for comparing the first visit vs. the fourth visit data sets was 
performed.  Table 6 (next page) shows the results according to the 
correlating question of the APCA African POS.  All domains showed a 
statistically significant change from first to fourth visit, with the p value in 
each instance being <0.0001.  Thus from a clinical point of view, every 
domain of palliative care shows significant improvement over time.  This 




























































































1. Pain first visit 145 3.8 3.7 to 4.0 1.0 1.0 26.3% 0.85 <0.0001 
      fourth visit 145 2.3 2.1 to 2.5 1.5 1.2 52.1% 0.92 <0.0001 
2. Other 
Symptoms first 
133 2.7 2.4 to 2.9 2.1 1.4 54.3% 0.92 <0.0001 
      fourth 133 1.5 1.3 to 1.7 1.7 1.3 87.7% 0.87 <0.0001 
3. Anxiety first   133 3.4 3.1 to 3.6 2.4 1.5 45.4% 0.86 <0.0001 
       fourth 132 2.1 1.8 to 2.3 2.1 1.4 70.0% 0.92 <0.0001 
4. Isolation first 133 3.5 3.2 to 3.8 2.7 1.6 46.9% 0.83 <0.0001 
      fourth 133 4.2 4.0 to 4.4 1.3 1.1 27.1% 0.74 <0.0001 
5. Despair first 133 1.9 1.6 to 2.2 3.0 1.7 91.5% 0.87 <0.0001 
      fourth 133 3.0 2.7 to 3.2 2.7 1.7 56.0% 0.90 <0.0001 
6. Peace first 133 1.8 1.6 to 2.1 2.4 1.5 83.6% 0.90 <0.0001 
      fourth 133 2.9 2.6 to 3.1 2.4 1.5 53.4% 0.92 <0.0001 
7. Planning  first 133 3.0 2.6 to 3.3 3.7 1.9 64.5% 0.84 <0.0001 
      fourth 133 4.1 3.9 to 4.3 1.3 1.2 28.4% 0.78 <0.0001 
8. Information 1 133 3.3 3.0 to 3.6 2.8 1.7 50.4% 0.86 <0.0001 
     fourth 133 4.6 4.4 to 4.7 0.5 0.7 15.1% 0.66 <0.0001 
9. Confidence in 
family caring  1 
133 4.1 3.8 to 4.3 1.4 1.2 29.7% 0.77 <0.0001 
      fourth 133 4.4 4.3 to 4.6 0.8 0.9 20.5% 0.67 <0.0001 
10. Family 
anxiety 
133 3.1 2.8 to 3.3 2.5 1.6 51.5% 0.90 <0.0001 





























Table 6:  Wilcoxon test comparing Visit 1 to Visit 4 for each Question 







Z statistic 2-tailed p 
1. Pain 145 1.5 1.5 to 1.5 5929 8.66 <0.0001 
2. Other 
Symptoms 
133 1.0 1.0 to 1.5 4487 7.42 <0.0001 
3. Anxiety 132 1.5 1.0 to 1.5 4721 7.36 <0.0001 
4. Isolation 133 -0.5 -0.5 to -0.5 350 -4.91 <0.0001 
5. Despair 133 -1.0 -1.0 to -0.5 406.5 -6.63 <0.0001 
6. Peace 133 -1.0 -1.5 to -0.5 853 -5.82 <0.0001 
7. Planning 133 -1.0 -1.5 to -0.5 381.5 -5.90 <0.0001 
8. Information 133 -1.0 -1.5 to -1.0 108.0 -7.26 <0.0001 
9. Confidence in 
family caring 
133 0.0 -0.5 to 0.0 88 -4.56 <0.0001 
10. Family 
anxiety 




145 APCA African POS were completed filled in with regards to pain.  For 
the remaining 9 questions all POS reports which had any blanks at all were 
























4.2  Nurse Interview Analysis 
The 11 interviews were subjected to thematic analysis using a cut and paste 
approach.  6 interviews were with CHAT nurses (no access to oral 
morphine) and 5 interviews were with Selian nurses (consistent access to 
oral morphine).  4 major thematic areas were noted:  morphine as a superior 
analgesic drug; holistic care as an important adjunct to pain management; 
and education of the family and patient as being very important, and 
palliative care being perceived as a life-prolonging service.  Table 7 lists the 
sub-themes and themes. 
 
Table 7:  Themes and Sub-themes 
Themes Sub-themes 
Morphine is Best 1. Belief that pain relief would be 
better with morphine 
2. Morphine increases Nurse 
confidence in the ability to 
control pain 
3. Cancer pain is almost always 
controlled with oral morphine 
Holistic Care is important 1. Holistic care is very important 
especially when pain control is 
poor 
2. Bereavement support is a 
usual and critical part of care 
3. Palliative care is important 
even without morphine 
Education is a valuable adjunct  
Palliative Care can extend life  
 
 
a) Morphine is best for pain 
 
i) Belief that Pain relief would be better with morphine:  5 of 6 
CHAT Nurses expressed the opinion that they could do a better job 
if they had oral morphine on hand for their patients.                        
 
“…if oral morphine was available people would find it less 












“The cases are few that are not helped by tramadol and ibuprofen, 
but these complicated cases with severe pain, I believe the 
availability of oral morphine would be a very big relief.” (CHAT 
Nurse 6) 
 
ii) Morphine increases Nurse confidence in the ability to control pain:  
4 CHAT Nurses and 1 Selian Nurse commented on this point.  
 
“It is a challenge (not having morphine), actually a very big one.  
You get there and you have nothing with which to help the pain.  
Sometimes the person needs help, and when you fail to deliver that 
help, it as if you have done nothing.  They may even wonder why 
you bothered to visit.” (CHAT Nurse 5) 
 
“Having morphine gives us confidence that even if our patient is 
near the end of life, we can do something.”  (CHAT Nurse 1) 
 
iii) Cancer pain is almost always controlled with oral morphine:  the 5 
Selian Nurses are unanimous on this point. 
     
“I do not remember such a case of someone not being helped by 
oral morphine.  Most patients get a good result.” (Selian Nurse 3)  
 
“I can’t remember one when we had morphine and we could not 
control the pain.” (Selian Nurse 5) 
 
 
b) Holistic Care provides important support beyond pain control. 
 
i) Holistic care is very important especially with cases where pain 
control is poor.  7 Nurses commented on this area, 2 from CHAT 
and 5 from Selian.  There were no specific questions asking about 
holistic care; these comments came out in the case narratives.  
Comments ranged from paying attention to odour to consideration 
of psychosocial pain due to limb amputation.   
 
“With our African setup you cannot simply say that now I 
managed the physical pain and everything is OK.  There are other 
aspects of pain like the social pain, the spiritual pain and so on.  











other pains like the social pain and the spiritual pain and 
psychosocial pain then you will find that to some extent a lot of 
these pains are associated with the physical.  For example there 
might be family conflicts, or poverty, the child is not going to 
school, the breadwinner is unable to work; so you find some of 
these elements are adding pain into the physical pain.”  (CHAT 
Nurse 3)   
 
“For such a case where pain is increasing even though we are 
giving the oral morphine, we have to do further assessment.  It is 
possible that the pain is spiritual, or psychological, and not only 
physical.  Such cases are here.”  (Selian Nurse 2) 
 
ii) Bereavement support is a usual part of the narration of care.  3 
CHAT Nurses and 1 Selian Nurse commented on follow-up care 
after the death of a client.  Attendance at the funeral was the 
primary theme.   
 
“Fortunately, we received the message of her death just after the 
event, and we had the chance to go as a team to attend the burial.”  
(CHAT Nurse 2)  
 
“...we had to embark on bereavement support and now we are 
supporting the family; the family wanted to share the properties 
and we worked so far to provide the death certificate.  They are 
planning next month to start sitting down to plan.” (CHAT Nurse 
3) 
   
iii) Palliative Care is important even without morphine.  This was a 
specific question near the end of each interview:  how did the 
Nurse feel about palliative care being delivered without oral 
morphine being available?  The response was unanimous in 
affirming that palliative care had value even without oral 
morphine.   
 
“By staying so close to patients and continuously asking them 
about pain, we keep hearing that their pain is getting better.  And 
this is without morphine.” (CHAT Nurse 2)    
 











approach, considering not only physical but also spiritual, 
psychological, and social aspects.  Pain can still be addressed with 
locally available drugs.  At least having tramadol, paracetamol, and 
ibuprofen should allow a team to work with most pain.”  (Selian 
Nurse 2) 
 
c) Education for patients and families is a valuable adjunct to care.  
5 Nurses (3 from CHAT, 2 from Selian) commented specifically on 
education as being an important part of their care.   
 
“They had given up, but we also showed them how to do wound 
dressings, how to continue with medications, so that they cared for her 
up to the time of her death.” (Selian Nurse 1)    
 
“So we try to spend time to educate and comfort families because the 
result is that they get peace.  Also, for them to understand that the 
particular illness does not have a cure; that their goals would be for 
the patient to be free of pain, and also that the family not get pain 
from the patient’s pain.  That is the big thing that we try to do, in 
comforting and educating families.”  (Selian Nurse 3) 
 
d) Palliative Care can extend life:  some comments did not fit into 
other categories and/or were too few to merit separate consideration as 
themes.  A few quotes had to do with care and pain control as related 
to life expectancy.   
 
“Pain makes people feel devastated and that is the end of the world, 
and sometimes they give up and die.” (CHAT Nurse 3)   
 
“...it was not the pain that killed her; rather it was her disease, the 
cancer.  Her pain was well-controlled up to the end.” (Selian Nurse 1)   
 
 “…our patients with severe pain are so grateful to be under palliative 
care services, and to be visited.  Many believe that without the care 
and treatment including attention to pain, they would have stopped 


















Figure 1 is another way of visualizing the results of the data analysis plus 
nursing interview analysis.  That tramadol has a significant effect is 
supported by the APCA African POS data.  That morphine is better is 
emphasized by the palliative care nurses.  Holistic care being effective has 
evidence from both the APCA African POS data plus the nurse interviews.  
Education is brought out as a specific additional point by the nurses. 
 
 










































Is “quality” palliative care able to be delivered in the absence of oral 
morphine?  This is one way of phrasing the research question of this study, 
and the results seem to indicate a very clear “yes”.  Overall pain scores 
improved from an average of 3.8/5 to 2.3/5.  Other quality of life indicators 
– non-pain symptoms, psychological, spiritual, and family issues - also 
improved significantly over time.  Nurses also affirmed the value of 
palliative care even in the absence of oral morphine.  There is no ambiguity, 
then:  in this rural Tanzanian setting, palliative care is valuable, and offers a 
significant degree of pain control, even in the absence of oral morphine. 
 
From the nursing side, there is an additional very clear point.  With oral 
morphine, there is the belief that pain control is even better.  Nurses working 
with morphine were unanimous in expressing confidence in dealing with 
cancer:  “I do not remember such a case of someone not being helped by oral 
morphine” (Selian Nurse 3).  Likewise, nurses without morphine all recalled 
difficult cases which may have been better had they only been able to access 
that drug. 
 
What are the weaknesses of this study?  Some potential ones might be: 
 There is no study group of sites which do have access to oral 
morphine.  It would have been a stronger study if a direct 
comparison would have been possible. 
 Having only one investigator doing APCA African POS 
assessments, interviews, and translations.  More than one 
investigator might have diminished any inherent bias coming from a 
single investigator. 
 Many languages were used, possibly impacting on the validity of the 
APCA African POS as well as the interviews.  Each rural 
community involved in this study works with 2 to 3 primary 
languages.  While Swahili is the dominant language in Tanzania, 
there are more than 120 distinct languages in the country, which is 
reflected in the 13 rural sites of this study.  Some APCA African 
POS interviews were conducted in a language other than Swahili.  
With nurse interviews and translation, cross-checking with another 
translator was not done due to cost and confidentiality concerns. 
 











environments, with a variety of dominant languages.  It is unlikely that the 
variances of rural Tanzania are strikingly different from those of Uganda, 
Kenya, South Africa, and Zimbabwe.  Tanzania might actually have an 
advantage in being more standardized with language, as Swahili is well-
understood by anyone who has attended primary level education. 
 
Regarding potential investigator bias, that might be an inherent issue with 
having a single person doing the vast majority of the work.  Cross-checking 
with colleagues and literature is helpful; a future or follow-up study might 
involve more than one investigator. 
 
Do these limitations impact on the study findings?  I would suggest that they 





Thus it is not surprising that tramadol is efficacious in a large 
number of cases.  There is even literature to suggest that, with more 
aggressive use of tramadol, pain outcomes might be even better
29,31
, as these 
papers suggest a morphine to tramadol equianalgesic ratio of closer to 1:5, 
rather than the more traditional 1:10 or even 1:20.  There is also experience 
in this literature of using up to 600 mg/d of oral tramadol, with equal or 
better side-effect profiles as compared to oral morphine.  There is the 
suggestion, then, that more aggressive use of tramadol than what was done 
in the CHAT setting – with a maximum dose of 400 mg/d – might result in 
even better pain score results. 
 
Results are also in line with other data from palliative care providers in 
Africa and the African Palliative Care Association
39
.  Loy’s work, again, 
shows the positive impact of palliative care for HIV clients.  Certainly it is 
expected that, apart from pain, other domains would likewise improve with 
holistic, intentional care.  As the nurse interviews point out, whether in 
wound care with odour control, bereavement support, or psychosocial and 
spiritual support, clients have a great appreciation and sense of improvement 
when receiving palliative care. 
 
“With our African setup you cannot simply say that now I managed 
the physical pain and everything is OK.  There are other aspects of 
pain like the social pain, the spiritual pain and so on.  They contribute 
a lot to pain and so if you are able to manage these other pains like the 
social pain and the spiritual pain and psychosocial pain then you will 
find that to some extent a lot of these pains are associated with the 











child is not going to school, the breadwinner is unable to work; so you 
find some of these elements are adding pain into the physical pain.”  
(CHAT Nurse 3) 
 
“Palliative care is not just oral morphine.  It takes the holistic 
approach, considering not only physical but also spiritual, 
psychological, and social aspects.  Pain can still be addressed with 
locally available drugs.  At least having tramadol, PCM, and 
ibuprofen should allow a team to work with most pain.”  (Selian 
Nurse 2) 
 
The APCA data, also not yet published, showed an average pain score of 
1.79/5 for cancer patients (n=89) who do have access to oral morphine and 
have been assessed multiple times
45
.  This compares to 2.31/5 in the current 
study.  Thus there is evidence to suggest that pain control is indeed better 
with oral morphine, even though a direct comparison was not undertaken.  
APCA African POS data is not available from the Selian team, which 
otherwise would have been a good source for comparison.  This would be an 
area for further study, utilizing data from the APCA African POS from rural 
Tanzanian sites which have access to oral morphine. 
 
What if tramadol was dosed more aggressively?  And what if the teaching 
regarding the WHO analgesic ladder was altered to suggest that tramadol is 
as potent as morphine in the Tanzanian setting?  There is the likelihood, not 
yet evaluated, that pain control would be even better, and approaching that 
expected from the use of oral morphine. 
 
In this study, nurse interviews affirm that oral morphine would be a 
preferable analgesic to tramadol, with only 1 of 13 nurses not being sure 
about wanting access to morphine for palliative care delivery. 
 
“I am sure that things would be different if we had oral morphine.  It 
is likely that pain would decrease more, and that with less pain the 
patient would have more faith.”  (CHAT Nurse 5)  
 
“The cases are few that are not helped by tramadol and ibuprofen, but 
these complicated cases with severe pain, I believe the availability of 
oral morphine would be a very big relief.”  (CHAT Nurse 6)  
 











usual drugs so well, having morphine would be a real challenge for 
me.  By staying so close to patients and continuously asking them 
about pain, we keep hearing that their pain is getting better.  And this 
is without morphine.” 
 
Notably, Selian nurses were extremely confident in achieving pain control 
with oral morphine.   
 
“No, I do not recall such cases.” (Cancer pain not controlled with 
morphine). (Selian Nurse 2) 
 
“I do not recall someone whose cancer pain does not respond to 
morphine.  If the pain increases, we titrate the dose accordingly.”  
(Selian Nurse 1)  
 
“I do not think so.  I don’t have any patient like that.  I can’t 
remember one when we had morphine and we could not control the 
pain.”  (Selian Nurse 5)   
 
There seems little danger of palliative care teams becoming complacent in 
their pursuit of oral morphine access. It might be construed that this study is 
a rationale for governments not to allow opioid access.  However, the strong 
international influence and training regarding opioid necessity for any 
quality of care is a definite push for the palliative care professionals 
delivering care to continuously advocate for oral morphine.  Richard Smith, 
former editor of the British Medical Journal, commented on attending a 
meeting about global palliative care: “Some 80% of people in the world lack 
access to morphine, and, as Anne Merriman, a pioneer of palliative care in 
Africa, says “Palliative care without morphine is only supportive care.” The 





This last point, the pursuit of oral morphine, is an ongoing challenge for 
many palliative care advocates around the world.  This study, and indeed the 
CHAT project and its associated emphasis on quality measurement, is an 
important advocacy for accessing oral morphine and for palliative care in 
general.  The provision of client-centred data is valuable in care provision.  
Typical measures for quality of care tend to focus on care provision (e.g. co-
trimoxazole or ARV adherence in HIV care, or access to radiation and/or 











making and health guidance from the government side.  Indeed, as 
Mmbando describes, it is due to this very emphasis on quality and advocacy 
that 12 of 13 CHAT sites (including all sites from which the Nurse 
interviewees come) have, as of February 2011, been granted approval for 




Hearn and Higgenson, in their 1997 review of over 20 different quality of 
life tools for palliative care, suggest that there are four potential purposes in 




Firstly, in order to provide clinical feedback for 
those who are gathering the data.  In this respect, the experience with CHAT 
was positive.  As teams learned and became comfortable with the tool, 
reliable and timely clinical feedback happened.  Interventions were 
implemented and impacted outcomes.  Secondly, the measures serve as an 
audit of services.  Again, the experience in this setting was positive.  
Outcomes were found to be positive in every domain measured, providing 
important positive feedback to teams, hospital management, and funders.  
Third, the measure can be an indicator of the value of a service as compared 
to before its implementation.  Here baseline “Visit 1” information is a fair 
indicator of usual care and outcomes without palliative care intervention.  
These are measures for people who have been through hospital systems and 
have a terminal diagnosis.  Their baseline prior to intervention:  3.8/5 pain, 
3.4/5 anxiety, to mention the highest, all show significant improvement over 
time.  Finally, the information becomes a resource for health systems in 
determining the value of paying for a service.  Governments and other 
funders of health care are able to look at this information and see 
improvement as measured by profoundly ill individuals and their families.  
Even without the best of tools, outcomes are very good.  Will purchasers of 
health care, particularly in a resource-constrained environment, include 
palliative care?  This research indicates that such a purchase might be 
expected to bring tangible results, even without oral morphine.  With oral 






















Even without access to oral morphine, palliative care is a potent intervention 
for pain control and other quality of life measures.  Tramadol provides a 
significant degree of pain relief even as a weak opioid, or “Level 2” 
analgesic according to the WHO analgesic ladder.  Nurses, however, are 
very aware of tramadol’s limitations in treating severe cancer pain, and are 
clear in having a preference for oral morphine. 
 
In 2009 the theme for the World Hospice Day was “Discovering your voice” 
(http://www.worldday.org/news/discover-your-voice/).  The cancer patients 
in this study were given a voice, telling us that palliative care is valuable 
with and without the provision of oral morphine.  Palliative care nurses also 
have a voice, and clearly state that, while palliative care is important, access 
to oral morphine is also very important.  As stated by Selian Nurse 5:  “With 
palliative care, it’s not only morphine.  It is morphine plus other cares that 
we have to give.  It is not a must that we have morphine, though it is 
critically needed, even in the rural areas.  In all of the health facilities it is 
needed, but palliative care is not only morphine.  We still have to give other 
cares, like spiritual care, the physical, the social and the psychological.  So, 
if they do not have morphine, yes, they can give the other analgesics, but 
still palliative care can continue with the other cares that we are supposed to 
give.  But while doing that we have to still look for some ways to get 
morphine, because there are so many patients in the rural areas who have 
cancer and they need morphine because of their pain.  And pain is really 
very destructive to patients, so something needs to be done; it needs to be 
taken care of.” 
Finally, the history of the CHAT program and the ongoing advocacy done 
by teams and supervisors clearly shows that palliative care provision in itself 
is an advocacy tool for accessing that most critical of analgesic drugs for 
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Table 2:  Average Scores per Visit 
 
Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) 
during the last 3 days 
 
 
0 (no pain) 
- 5 (worst/overwhelming pain) 
Visit 1 Visit 2 Visit 3 Visit 4 
  3.83   3.08   2.72   2.31 
 
Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been 
affecting how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.58 
 
  2.05 
 
  1.68 
 
  1.50 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.39 
 
  2.67 
 
  2.31 
 
  2.10 
 
Q4. Over the past 3 days, have you been able to share how you are feeling 
with your family or friends? 
 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.46/ 
  1.54 
  3.84/ 
  1.16 
  4.06/ 
  0.94 
  4.15/ 
  0.85 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  1.95/ 
  3.05 
  2.52/ 
  2.48 
  2.94/ 
  2.06 
  2.95/ 
  2.05 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.80/ 
  3.20 
  2.39/ 
  2.61 
  2.73/ 
  2.27 
  2.84/ 
  2.16 
 
Q7 Have you had enough help and advice for your family to plan for the 
future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  2.94/ 
  2.06 
  3.70/ 
  1.30 
  3.99/ 
  1.01 
  4.08/ 
  0.92 
 
Q8. How much information have you and your family been given? 
0 (none) 




  3.30/ 
  1.70 
 
  4.01/ 
  0.99 
 
  4.40/ 
  0.60 
 
  4.63/ 
  0.37 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.09/ 
  0.91 
  4.34/ 
  0.66 
  4.45/ 
  0.55 
  4.46/ 
  0.54 
 
Q10. Has the family been feeling worried about the patient over the last 3 
days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  3.08 
 
  2.58 
 
  2.19 
 
  2.10 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 
 











Table 3:  Average Scores  Female 
 
Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) 
during the last 3 days 
 
0 (no pain) 
- 5 (worst/overwhelming pain) 
Visit 1 Visit 2 Visit 3 Visit 4 
  3.71   2.99   2.67   2.31 
 
Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been 
affecting how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.57 
 
  2.02 
 
  1.55 
 
  1.47 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.44 
 
  2.75 
 
  2.41 
 
  2.27 
 
Q4. Over the past 3 days, have you been able to share how you are feeling 
with your family or friends? 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.41/ 
  1.59 
  3.79/ 
  1.21 
  3.94/ 
  1.06 
  4.03/ 
  0.97 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  2.01/ 
  2.99 
  2.49/ 
  2.51 
  2.93/ 
  2.07 
  2.85/ 
  1.90 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.84/ 
  3.16 
  2.36/ 
  2.64 
  2.70/ 
  2.30 
  2.75/ 
  2.25 
 
Q7 Have you had enough help and advice for your family to plan for the 
future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  2.81/ 
  2.19 
  3.64/ 
  1.36 
  3.87/ 
  1.13 
  3.99/ 
  1.01 
 
Q8. How much information have you and your family been given? 
0 (none) 
- 5 (as much as wanted) 
N/A 
 
  3.28/ 
  1.72 
  3.95/ 
  1.05 
  4.31/ 
  0.69 
  4.49/ 
  0.51 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.07/ 
  0.93 
  4.32/ 
  0.68 
  4.44/ 
  0.56 
  4.41/ 
  0.59 
 
Q10. Has the family been feeling worried about the patient over the last 3 
days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  3.14 
 
  2.58 
 
  2.21 
 
  2.16 
 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 
  
  2.54 
 
  1.98 
 
  1.67 
 











Table 4:  Average Scores Male 
 
Q1. Please rate your pain (from 0 = no pain to 5 = worst/overwhelming pain) 
during the last 3 days 
 
 
0 (no pain) 
- 5 (worst/overwhelming pain) 
Visit 1 Visit 2 Visit 3 Visit 4 
  4.02   3.21   2.81   2.31 
 
Q2. Have any other symptoms (e.g. nausea, coughing or constipation) been 
affecting how you feel in the last 3 days? 
 
 
0 (not at all) 
- 5 (overwhelmingly) 
 
 
  2.59 
 
  2.09 
 
  1.86 
 
  1.55 
 
Q3. Have you been feeling worried about your illness in the past 3 days? 
 
 
0 (not at all) 
- 5 (overwhelming worry) 
 
  3.31 
 
  2.54 
 
  2.14 
 
  1.81 
 
Q4. Over the past 3 days, have you been able to share how you are feeling 
with your family or friends? 
 
0 (not at all) 
- 5 (yes, I’ve talked freely) 
  3.52/ 
  1.48 
  3.91/ 
  1.09 
  4.22/ 
  0.78 
  4.33/ 
  0.67 
 
Q5. Over the past 3 days have you felt that life was worthwhile? 
 
 
0 (no, not at all) 
- 5 (Yes, all the time) 
  1.86/ 
  3.14 
  2.57/ 
  2.43 
  2.97/ 
  2.03 
  3.10/ 
  1.90 
 
Q6. Over the past 3 days, have you felt at peace? 
0 (no, not at all) 
- 5 (Yes, all the time) 
 
  1.74/ 
  3.26 
  2.45/ 
  2.55 
  2.78/ 
  2.22 
  2.98/ 
  2.02 
 
Q7 Have you had enough help and advice for your family to plan for the 
future? 
0 (not at all) 
- 5 (as much as wanted) 
 
  3.12/ 
  1.88 
  3.79/ 
  1.21 
  4.17/ 
  0.83 
  4.22/ 
  0.78 
 
Q8. How much information have you and your family been given? 
0 (none) 
- 5 (as much as wanted) 
N/A 
 
  3.33/ 
  1.67 
  4.11/ 
  0.89 
  4.54/ 
  0.46 
  4.67/ 
  0.33 
 
Q9. How confident does the family feel caring for ____? 
 
0 (not at all) 
- 5 (very confident) 
N/A 
  4.11/ 
  0.89 
  4.38/ 
  0.62 
  4.48/ 
  0.52 
  4.53/ 
  0.47 
 
Q10. Has the family been feeling worried about the patient over the last 3 
days? 
0 (not at all) 
- 5 (severe worry) 
N/A 
 
  2.98 
 
  2.59 
 
  2.16 
 
  2.02 
AVERAGE “GLOBAL SCORE” on a 0 – 5 scale where 0 is good 
 











Each red cross represents an ELCT hospital.  4 additional hospitals have opened or are in 
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Study Title:  Assessing the Quality of Palliative Care in Rural Tanzania 
where Availability of Oral Morphine is Intermittent or Absent 
 




I am undertaking a Masters Degree in Palliative Care out of the University 
of Capetown in South Africa.  Part of the research of the above study is to 
conduct interviews with Nurses who are involved with the delivery of 
palliative care. 
 
The interview is designed to be about 30 minutes in length.  You will be 
asked some basic questions about the challenges of helping people with 
severe pain, especially those living with cancer.  If there are questions you 
prefer not to answer, you may feel free to move on.  Should you desire to 
stop the interview at any point you may feel free to do so.  You may also 
feel free to expand on the questions and talk about related issues according 
to your experience. 
 
All of the information will be kept confidential with regards to names of 
those being interviewed.  The data will be kept in a secure place during and 
after the study.  The results will be submitted to the University of Capetown. 
 
Participant’s Agreement: 
I understand that my participation in the interview is entirely voluntary.  I 
understand the intent and purpose of the research.  If I wish to stop the 
interview for any reason, I may do so without having to give an explanation. 
 
The researcher has reviewed the particular benefits and risks of this project 
with me.  I understand that this study is part of a course being undertaken by 
the researcher.  I understand that the results will be available through the 
library of the U. of Capetown.  I have the right to withdraw or review any 
information I have given prior to the submission of the results.  I understand 
that the data is to be collected by way of tape recording, and will be kept 
confidential in regards to my personal identity.  If I choose to have the tape 
stopped and erased to any extent, I am free to do so. 
 
Should I have any questions about this study I may contact the researcher.  I 












































Re:  Notice of Research Being Conducted in Palliative Care 
 
Please regard the above heading.  I am presently enrolled in the Masters 
Degree in Palliative Care out of the University of Capetown in South Africa.  
My research thesis is entitled:  “Assessing the Quality of Palliative Care in 
Rural Tanzania where Availability of Oral Morphine is Intermittent or 
Absent.” 
 
There are two components to this research.  One is a retrospective analysis 
of data which has already been collected through our CHAT program, in 
particular the APCA POS which your team uses as an assessment tool on a 
regular basis.  This data will be assessing pain control and quality of life for 
people living with cancer who have been served by your palliative care 
team.  Our database does not have the patient names, but rather only their 
identification numbers, thereby assuring complete confidentiality. 
 
The second component of the research is to conduct interviews with Nurses 
who are directly involved in Palliative Care.  It is possible that we will be 
asking your Palliative Care Nurse to participate in one the interviews.  In 
that event the interview would happen during a site visit from our CHAT 
team or during one of the management meetings in Arusha.  The names of 
interviewees will be kept confidential. 
 
This research will have passed through all relevant channels of the Tanzania 
National Medical Research Institute prior to the initiation of any activities. 
 
Your consent for this process will be most appreciated.  For any questions or 
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HREC REF: 319/2010 
DrKHartwig 
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School of Public Health & Family Medicine 
Dear Dr Hartwig 
Faculty of Health Sciences Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Obse~ator:y 7925 
Telephone [021)4D6 6338 • Facsimile [021)4D6 6411 
c-mall: sumayah.ariefdien@uct.ac.za 
PROJECT TITLE: AN EVALUATION OF PALLIATIVE CARE IN RURAL TANZANIA 
WHERE AVAILABILITY OF ORAL MORPHINE IS INTERMlTIENT OR ABSENT 
TIlank you for submitting your study to the Health Science Faculty Research Ethics Committee for review 
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Approval is granted fOf one year till the 15th August 2011. 
Please submit a progress form, using the standardised Anoual Repo.tt Fo.rm (FH$016), if the study continues 
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1. Introduction of the Nurse including site of work and personal
history in palliative care work.
2. Have the Nurse describe in detail the case of a patient with cancer who, while
under their team’s care, had poor pain control.
3. Have the Nurse describe in detail the case of a patient with cancer who, while
under their team’s care, had very good pain control.
4. Ask the Nurse to reflect on the value of palliative care in the setting of no access
to oral morphine for chronic pain control.
